{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:59:20Z","timestamp":1785495560619,"version":"3.56.0"},"reference-count":16,"publisher":"Akademiai Kiado Zrt.","issue":"49","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,12,7]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    Az alopecia areata a nem heges alopeci\u00e1k k\u00f6z\u00e9 tartoz\u00f3\n                    autoimmun betegs\u00e9g. Magyarorsz\u00e1gon s\u00falyos alopecia areata indik\u00e1ci\u00f3ban a\n                    baricitinib \u00e9s a ritlecitinib JAK-g\u00e1tl\u00f3kat t\u00f6rzsk\u00f6nyvezt\u00e9k, amelyek\n                    hat\u00e9konys\u00e1g\u00e1t multicentrikus klinikai vizsg\u00e1latok eredm\u00e9nyei t\u00e1masztj\u00e1k al\u00e1.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    Retrospekt\u00edv m\u00f3don vizsg\u00e1ltuk s\u00falyos alopecia\n                    areata miatt baricitinibkezel\u00e9sben r\u00e9szes\u00fcl\u0151 betegeinkn\u00e9l a ter\u00e1pia hat\u00e1soss\u00e1g\u00e1t\n                    \u00e9s biztons\u00e1goss\u00e1g\u00e1t, illetve a hajvisszan\u00f6v\u00e9st befoly\u00e1sol\u00f3 t\u00e9nyez\u0151ket.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    A Szegedi Tudom\u00e1nyegyetem Szent-Gy\u00f6rgyi Albert\n                    Orvostudom\u00e1nyi Kar\u00e1nak B\u0151rgy\u00f3gy\u00e1szati \u00e9s Allergol\u00f3giai Klinik\u00e1j\u00e1n alopecia\n                    areata miatt baricitinibbel kezelt betegek demogr\u00e1fiai adatait, k\u00f3rt\u00f6rt\u00e9net\u00e9t, a\n                    betegs\u00e9g fenn\u00e1ll\u00e1s\u00e1nak id\u0151tartam\u00e1t \u00e9s s\u00falyoss\u00e1g\u00e1t elemezt\u00fck. A betegs\u00e9g\n                    s\u00falyoss\u00e1g\u00e1t a Severity of Alopecia Tool (SALT) seg\u00edts\u00e9g\u00e9vel m\u00e9rt\u00fck. Vizsg\u00e1ltuk a\n                    hajvisszan\u00f6v\u00e9s megjelen\u00e9s\u00e9hez, illetve a teljes hajvisszan\u00f6v\u00e9shez sz\u00fcks\u00e9ges\n                    id\u0151t. Megvizsg\u00e1ltuk, hogy a kezel\u00e9s 3., 6., 9. \u00e9s 12. h\u00f3napj\u00e1ban a betegek\n                    milyen ar\u00e1nyban \u00e9rt\u00e9k el a SALT\u226420 \u00e9rt\u00e9ket.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    \u00d6sszesen 20 n\u0151t \u00e9s 10 f\u00e9rfit vizsg\u00e1ltunk, \u00e1tlag\u00e9letkoruk 33 (9\u201356) \u00e9v volt. A\n                    klinikai form\u00e1k k\u00f6z\u00fcl el\u0151fordult foltos (n = 13), diff\u00faz (n = 1), ophiasis\n                    t\u00edpus\u00fa (n = 2), alopecia totalis (n = 4) \u00e9s alopecia universalis (n = 12), a\n                    kiindul\u00e1si \u00e1tlag-SALT-pontsz\u00e1m 74 volt. Az ut\u00e1nk\u00f6vet\u00e9si id\u0151 \u00e1tlaga 14 h\u00f3nap\n                    (3\u201324 h\u00f3nap) volt. Hajvisszan\u00f6v\u00e9st el\u0151sz\u00f6r \u00e1tlagosan 4 h\u00f3nappal (1\u201315 h\u00f3nap),\n                    teljes hajvisszan\u00f6v\u00e9st (n = 16) pedig 10 h\u00f3nappal (2\u201319 h\u00f3nap) a ter\u00e1pia\n                    ind\u00edt\u00e1s\u00e1t k\u00f6vet\u0151en \u00e9szlelt\u00fcnk. A SALT\u226420 \u00e9rt\u00e9ket 3 h\u00f3nap ut\u00e1n a betegek 23%-a, 6\n                    h\u00f3nap ut\u00e1n a 46%-a, 9 h\u00f3nap ut\u00e1n a 46%-a, 12 h\u00f3nap ut\u00e1n pedig a 63%-a \u00e9rte el. A\n                    kezel\u00e9s sor\u00e1n laborelt\u00e9r\u00e9sek, fejf\u00e1j\u00e1s, herpes simplex, acne, s\u00falygyarapod\u00e1s \u00e9s\n                    ban\u00e1lis infekci\u00f3k jelentkeztek. A ter\u00e1pi\u00e1t 6 betegn\u00e9l f\u00fcggesztett\u00fck fel:\n                    gyermekv\u00e1llal\u00e1si terv (n = 3), hat\u00e1stalans\u00e1g (n = 1), enyhe mell\u00e9khat\u00e1sok (n =\n                    1), illetve a kontroll elmulaszt\u00e1sa miatt (n = 1).\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    Eredm\u00e9nyeink al\u00e1t\u00e1masztj\u00e1k a\n                    baricitinibkezel\u00e9s hat\u00e1soss\u00e1g\u00e1t alopecia areat\u00e1ban. A betegek jelent\u0151s r\u00e9sz\u00e9n\u00e9l\n                    m\u00e1r a kezel\u00e9s 3. h\u00f3napj\u00e1ban megfigyelhet\u0151 volt a hajvisszan\u00f6v\u00e9s, ez az ar\u00e1ny a\n                    12. h\u00f3napra tov\u00e1bb n\u00f6vekedett. A mell\u00e9khat\u00e1sok t\u00f6bbnyire enyh\u00e9k voltak, csak egy\n                    esetben vezettek a ter\u00e1pia le\u00e1ll\u00edt\u00e1s\u00e1hoz. A baricitinib hat\u00e9kony \u00e9s biztons\u00e1gos\n                    kezel\u00e9s s\u00falyos alopecia areat\u00e1ban. Orv Hetil. 2025; 166(49): 1943\u20131948.\n                  <\/jats:p>","DOI":"10.1556\/650.2025.33444","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T04:44:51Z","timestamp":1765082691000},"page":"1943-1948","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Az alopecia areata kezel\u00e9s\u00e9ben alkalmazott baricitinib hat\u00e1soss\u00e1g\u00e1nak \u00e9s biztons\u00e1goss\u00e1g\u00e1nak retrospekt\u00edv vizsg\u00e1lata"],"prefix":"10.1556","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7084-073X","authenticated-orcid":true,"given":"Petra","family":"R\u00f3zsa","sequence":"first","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, B\u0151rgy\u00f3gy\u00e1szati \u00e9s Allergol\u00f3giai Klinika Szeged, Kor\u00e1nyi fasor 6., 6720 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Sz\u00e1sz","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le\u00f3","family":"Asztalos","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, B\u0151rgy\u00f3gy\u00e1szati \u00e9s Allergol\u00f3giai Klinika Szeged, Kor\u00e1nyi fasor 6., 6720 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Kem\u00e9ny","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, B\u0151rgy\u00f3gy\u00e1szati \u00e9s Allergol\u00f3giai Klinika Szeged, Kor\u00e1nyi fasor 6., 6720 Magyarorsz\u00e1g"},{"name":"HUN-REN\u2013SZTE, Dermatol\u00f3giai Kutat\u00f3csoport Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolland","family":"Gyulai","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, B\u0151rgy\u00f3gy\u00e1szati \u00e9s Allergol\u00f3giai Klinika Szeged, Kor\u00e1nyi fasor 6., 6720 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Sibbald C, Castelo-Soccio L. Review of global epidemiology data for\n                    alopecia areata highlights gaps and a call for action. Br J Dermatol. 2024; 191:\n                    315-316. https:\/\/doi.org\/10.1093\/bjd\/ljae088","DOI":"10.1093\/bjd\/ljae088"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia\n                    areata: a scoping review focusing on quality of life, mental health and work\n                    productivity. J Eur Acad Dermatol Venereol. 2023; 37: 1490-1520.\n                        https:\/\/doi.org\/10.1111\/jdv.18926","DOI":"10.1111\/jdv.18926"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Lee S, Lee H, Lee CH, et al. Comorbidities in alopecia areata: a\n                    systematic review and meta-analysis. J Am Acad Dermatol. 2019; 80: 466-477.e16.\n                        https:\/\/doi.org\/10.1016\/j.jaad.2018.07.013","DOI":"10.1016\/j.jaad.2018.07.013"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Tak\u00e1cs I, Dank M, Majnik J, et al. Hungarian consensus\n                    recommendation on the role of vitamin D in disease prevention and treatment.\n                    [Magyarorsz\u00e1gi konszenzusaj\u00e1nl\u00e1s a D-vitamin szerep\u00e9r\u0151l a betegs\u00e9gek\n                    megel\u0151z\u00e9s\u00e9ben \u00e9s kezel\u00e9s\u00e9ben.] Orv Hetil. 2022; 163: 575-584. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2022.32463","DOI":"10.1556\/650.2022.32463"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Ol\u00e1h K, N\u00e9meth T. Discovering the pathogenesis of autoimmune\n                    inflammation. [Az autoimmun gyullad\u00e1s h\u00e1tter\u00e9ben \u00e1ll\u00f3 folyamatok megismer\u00e9s\u00e9nek\n                    lehet\u0151s\u00e9gei.] Orv Hetil. 2024; 165: 983-996. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2024.33066","DOI":"10.1556\/650.2024.33066"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Pratt CH, King LE Jr, Messenger AG, et al. Alopecia areata. Nat Rev\n                    Dis Primers 2017; 3: 17011.\n                    https:\/\/doi.org\/10.1038\/nrdp.2017.11","DOI":"10.1038\/nrdp.2017.11"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Jadeja SD, Tobin DJ. Autoantigen discovery in the hair loss\n                    disorder, alopecia areata: implication of post-translational modifications.\n                    Front Immunol. 2022; 13: 890027.\n                        https:\/\/doi.org\/10.3389\/fimmu.2022.890027","DOI":"10.3389\/fimmu.2022.890027"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert\n                    consensus statement on the systemic treatment of alopecia areata. J Eur Acad\n                    Dermatol Venereol. 2024; 38: 687-694.\n                        https:\/\/doi.org\/10.1111\/jdv.19768","DOI":"10.1111\/jdv.19768"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Solt\u00e9sz L, G\u00e1sp\u00e1r K, Kapit\u00e1ny A, et al. Expanding knowledge in\n                    atopic dermatitis. [B\u0151v\u00fcl\u0151 tud\u00e1sunk az atopi\u00e1s dermatitis ter\u00fclet\u00e9n.] Orv Hetil.\n                    2024; 165: 1602-1612. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2024.33136","DOI":"10.1556\/650.2024.33136"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib\n                    for alopecia areata. N Engl J Med. 2022; 386: 1687-1699.\n                        https:\/\/doi.org\/10.1056\/NEJMoa2110343","DOI":"10.1056\/NEJMoa2110343"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of\n                    baricitinib in patients with severe alopecia areata over 52 weeks of continuous\n                    therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol.\n                    2023; 24: 443-451.\n                    https:\/\/doi.org\/10.1007\/s40257-023-00764-w","DOI":"10.1007\/s40257-023-00764-w"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Wada-Irimada M, Takahashi T, Sekine M, et al. Predictive factors for\n                    treatment responses to baricitinib in severe alopecia areata: a retrospective,\n                    multivariate analysis of 70 cases from a single center. J Dermatol. 2025; 52:\n                    701-711. https:\/\/doi.org\/10.1111\/1346-8138.17641","DOI":"10.1111\/1346-8138.17641"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"King B, Shapiro J, Ohyama M, et al. When to expect scalp hair\n                    regrowth during treatment of severe alopecia areata with baricitinib: insights\n                    from trajectories analyses of patients enrolled in two phase III trials. Br J\n                    Dermatol. 2023; 189: 666-673.\n                    https:\/\/doi.org\/10.1093\/bjd\/ljad253","DOI":"10.1093\/bjd\/ljad253"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Moussa A, Bennett M, Wall D, et al. The Alopecia Areata Severity and\n                    Morbidity Index (ASAMI) study: results from a global expert consensus exercise\n                    on determinants of alopecia areata severity. JAMA Dermatol. 2024; 160: 341-350.\n                        https:\/\/doi.org\/10.1001\/jamadermatol.2023.5869","DOI":"10.1001\/jamadermatol.2023.5869"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Xi L, Peeva E, Yamaguchi Y, et al. Multiomics analysis of the\n                    response to ritlecitinib in alopecia areata subtypes and correlation with\n                    efficacy. Allergy 2025; 80: 2348-2360.\n                        https:\/\/doi.org\/10.1111\/all.16659","DOI":"10.1111\/all.16659"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Pavel AB, Diaz A, et al. Ritlecitinib and\n                    brepocitinib demonstrate significant improvement in scalp alopecia areata\n                    biomarkers. J Allergy Clin Immunol. 2022; 149: 1318-1328.\n                        https:\/\/doi.org\/10.1016\/j.jaci.2021.10.036","DOI":"10.1016\/j.jaci.2021.10.036"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/49\/article-p1943.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/49\/article-p1943.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/49\/article-p1943.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:16:12Z","timestamp":1785492972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/49\/article-p1943.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":16,"journal-issue":{"issue":"49"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33444","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]}}}